Olema Pharmaceuticals (OLMA) Institutional Ownership

During the previous two years, 126 institutional investors and hedge funds held shares of Olema Pharmaceuticals. The most heavily invested institutionals were Bain Capital Life Sciences Investors LLC ($43.55M), Paradigm Biocapital Advisors LP ($42.59M), Logos Global Management LP ($34.72M), BVF Inc. IL ($33.32M), State Street Corp ($23.52M), Vivo Capital LLC ($23.14M), and Point72 Asset Management L.P. ($21.40M).Learn more on OLMA's institutional investors.

91.78% of Olema Pharmaceuticals stock is owned by institutional investors. Learn more on OLMA's institutional investor holdings.

Of the 100 institutional investors that purchased Olema Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($7.47M), Point72 Asset Management L.P. ($3.69M), Lightspeed Management Company L.L.C. ($1.93M), Paradigm Biocapital Advisors LP ($1.80M), Avoro Capital Advisors LLC ($1.65M), MPM Bioimpact LLC ($1.63M), and Wellington Management Group LLP ($1.18M).

Institutional investors have bought a total of 33,062,786 shares in the last 24 months. This purchase volume represents approximately $272.02M in transactions.

Of the 48 institutional investors that sold Olema Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: BVF Inc. IL ($3.42M), Kynam Capital Management LP ($1.78M), Sectoral Asset Management Inc. ($1.42M), Logos Global Management LP ($1.18M), Victory Capital Management Inc. ($758.41K), Deep Track Capital LP ($557.17K), and Vontobel Holding Ltd. ($362.53K).

Institutional investors have sold a total of 11,611,594 shares in the last 24 months. This volume of shares sold represents approximately $96.13M in transactions.